Last reviewed · How we verify
pneumoniae bacteremia therapy
At a glance
| Generic name | pneumoniae bacteremia therapy |
|---|---|
| Also known as | Total antibiotic treatment duration |
| Sponsor | Methodist Health System |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Gram-Negative Bloodstream Infection Oral Antibiotic Therapy Trial (NA)
- Short Versus Long Duration of Therapy for Streptococcus Pneumoniae Bloodstream Infections
- Clinical Evaluation of Novel Biomarkers in Patients With Septicemia
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- pneumoniae bacteremia therapy CI brief — competitive landscape report
- pneumoniae bacteremia therapy updates RSS · CI watch RSS
- Methodist Health System portfolio CI